India logs 38,667 cases; First Nasal Vaccine Approved for Phase 2 Trials

Story Highlights
  • 38,667 infections recorded
  • First nasal vaccine against COVID-19 scheduled for phase 2 trials
  • Kerala to conduct an extensive three day vaccination drive in contaminant zones

New Delhi: India reported 38,667 fresh infections in the past 24 hours. The recovery rate at 97.45 percent accounted for 35,743 recuperations in the last 24 hours taking the total recoveries to 3,13,38,088. The daily positivity rate stood at 1.73 per cent, less than 3 per cent for 19 consecutive days. 

The number of active cases stands at 3,87,673 accounting for 1.21 per cent of the total number of cases. The active cases reported a rise of 2,446 cases in the last 24 hours. However, the mortality rate recorded at 1.34 per cent reported 478 deaths, taking the cumulative death toll to 4,30,732.

First nasal vaccine against COVID-19 developed by Bharat Biotech got a regulator nod for phase 2 trial. In the meanwhile, Kerala has planned to inoculate all non-COVID individuals in the contaminant zones from today onwards for the coming three days. The official data released by MoHFW, reported no COVID related deaths in the capital in the last 24 hours were observed for the third day today. However, 50 new cases were detected.

As per MoHFW, 53,61,89,903 vaccines were administered in the past 24 hours. So far 63.80 crore beneficiaries have been immunized under the nationwide vaccination drive. As per ICMR, 22,97,798 infected samples have been tested in the past 24 hours. The cumulative count of tests done since the outbreak stands at 49.17 crores.

Read From India, Click here

Join our whatsapp Group to read news

Related Articles

Back to top button